FI4228676T3 - Koostumuksia, jotka sopivat vastasyntyneillä käytettäviksi - Google Patents
Koostumuksia, jotka sopivat vastasyntyneillä käytettäviksi Download PDFInfo
- Publication number
- FI4228676T3 FI4228676T3 FIEP21807381.5T FI21807381T FI4228676T3 FI 4228676 T3 FI4228676 T3 FI 4228676T3 FI 21807381 T FI21807381 T FI 21807381T FI 4228676 T3 FI4228676 T3 FI 4228676T3
- Authority
- FI
- Finland
- Prior art keywords
- composition
- concentration
- present
- hours
- polysorbate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 8
- 239000004094 surface-active agent Substances 0.000 claims 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 4
- 229920000136 polysorbate Polymers 0.000 claims 4
- 229950008882 polysorbate Drugs 0.000 claims 4
- 239000001632 sodium acetate Substances 0.000 claims 4
- 235000017281 sodium acetate Nutrition 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 3
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 claims 3
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 claims 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
- 206010022840 Intraventricular haemorrhage Diseases 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1754—Insulin-like growth factor binding proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063093696P | 2020-10-19 | 2020-10-19 | |
| PCT/US2021/055598 WO2022086953A1 (en) | 2020-10-19 | 2021-10-19 | Compositions suitable for use in neonates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4228676T3 true FI4228676T3 (fi) | 2025-02-26 |
Family
ID=78622033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21807381.5T FI4228676T3 (fi) | 2020-10-19 | 2021-10-19 | Koostumuksia, jotka sopivat vastasyntyneillä käytettäviksi |
Country Status (24)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250099541A1 (en) | 2022-01-19 | 2025-03-27 | Oak Hill Bio Ltd | Compositions and methods for reducing oxidation of igf-1/igfbp |
| CA3248280A1 (en) | 2022-05-04 | 2023-11-09 | Oak Hill Bio Limited | POLYTHERAPY FOR PREMATURE INFANTS |
| WO2023242439A1 (en) * | 2022-06-17 | 2023-12-21 | Oak Hill Bio Limited | Vascular stabilisation (preterm infants) |
| WO2023242440A1 (en) * | 2022-06-17 | 2023-12-21 | Oak Hill Bio Limited | Treament of lungs in infants |
| EP4598630A1 (en) * | 2022-10-04 | 2025-08-13 | Oak Hill Bio Limited | Method of treating neonates with igf-1 complex |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| ATE90690T1 (de) | 1987-04-06 | 1993-07-15 | Celtrix Pharma | Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung. |
| DK131988A (da) | 1988-03-11 | 1989-09-12 | Erasmus University | Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur |
| US5258287A (en) | 1988-03-22 | 1993-11-02 | Genentech, Inc. | DNA encoding and methods of production of insulin-like growth factor binding protein BP53 |
| ATE132164T1 (de) | 1988-04-12 | 1996-01-15 | Amgen Boulder Inc | Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors |
| GB8826451D0 (en) | 1988-11-11 | 1988-12-14 | Sandoz Ltd | Improvements in/relating to organic compounds |
| IL92816A0 (en) | 1988-12-22 | 1990-09-17 | Biogrowth Inc | Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides |
| EP0639981A4 (en) | 1992-05-08 | 1995-06-28 | Univ Jefferson | ANALOGS OF THE IGF FACTOR (01/18/94). |
| US5563046A (en) | 1993-08-02 | 1996-10-08 | Celtrix Pharmaceuticals, Inc. | Fusion polypeptides and proteins |
| US5789547A (en) | 1995-06-07 | 1998-08-04 | Celtrix Pharmaceuticals, Inc. | Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding |
| US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
| EP0956041A1 (en) * | 1996-09-16 | 1999-11-17 | Dalhousie University | Use of igf-i for the treatment of polycystic kidney disease and related indications |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| US6436897B2 (en) * | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| US20020028764A1 (en) * | 2000-09-04 | 2002-03-07 | Aarhus Amt. | Treatment of acute and chronic liver disease |
| JP2008543839A (ja) * | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| RU2558821C2 (ru) * | 2009-11-17 | 2015-08-10 | Ипсен Фарма С.А.С. | ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1 |
| US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| CA2897062A1 (en) * | 2013-01-15 | 2014-07-24 | Teva Pharmaceutical Industries Ltd. | Lyophilization process |
| KR20140119396A (ko) * | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| EP3681602B1 (en) * | 2017-09-11 | 2026-04-15 | Oak Hill Bio Limited | Compositions for reducing the incidence of bpd |
| US20250099541A1 (en) * | 2022-01-19 | 2025-03-27 | Oak Hill Bio Ltd | Compositions and methods for reducing oxidation of igf-1/igfbp |
| WO2023139250A1 (en) * | 2022-01-24 | 2023-07-27 | Oak Hill Bio Limited | Lot release assays for igf‐1/igfbp complexes |
-
2021
- 2021-10-19 KR KR1020237016217A patent/KR20230113287A/ko active Pending
- 2021-10-19 JP JP2023548542A patent/JP7827315B2/ja active Active
- 2021-10-19 ES ES21807381T patent/ES3005966T3/es active Active
- 2021-10-19 RS RS20250138A patent/RS66493B1/sr unknown
- 2021-10-19 CN CN202180071124.7A patent/CN117098547A/zh active Pending
- 2021-10-19 FI FIEP21807381.5T patent/FI4228676T3/fi active
- 2021-10-19 US US18/249,414 patent/US20230381285A1/en active Pending
- 2021-10-19 TW TW110138769A patent/TWI912393B/zh active
- 2021-10-19 CA CA3194764A patent/CA3194764A1/en active Pending
- 2021-10-19 PT PT218073815T patent/PT4228676T/pt unknown
- 2021-10-19 HU HUE21807381A patent/HUE070409T2/hu unknown
- 2021-10-19 SM SM20250093T patent/SMT202500093T1/it unknown
- 2021-10-19 WO PCT/US2021/055598 patent/WO2022086953A1/en not_active Ceased
- 2021-10-19 HR HRP20250193TT patent/HRP20250193T1/hr unknown
- 2021-10-19 PL PL21807381.5T patent/PL4228676T3/pl unknown
- 2021-10-19 MX MX2023004426A patent/MX2023004426A/es unknown
- 2021-10-19 LT LTEPPCT/US2021/055598T patent/LT4228676T/lt unknown
- 2021-10-19 AU AU2021364523A patent/AU2021364523A1/en active Pending
- 2021-10-19 SI SI202130265T patent/SI4228676T1/sl unknown
- 2021-10-19 DK DK21807381.5T patent/DK4228676T3/da active
- 2021-10-19 EP EP21807381.5A patent/EP4228676B1/en active Active
- 2021-10-19 IL IL301688A patent/IL301688A/en unknown
- 2021-10-19 EP EP24221637.2A patent/EP4534073A3/en active Pending
-
2023
- 2023-02-28 ZA ZA2023/03162A patent/ZA202303162B/en unknown
- 2023-04-06 SA SA523440271A patent/SA523440271B1/ar unknown
-
2026
- 2026-02-18 JP JP2026024189A patent/JP2026102579A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT4228676T (pt) | 2025-01-24 |
| JP2026102579A (ja) | 2026-06-23 |
| SMT202500093T1 (it) | 2025-03-12 |
| IL301688A (en) | 2023-05-01 |
| WO2022086953A9 (en) | 2022-07-07 |
| AU2021364523A1 (en) | 2023-04-06 |
| JP2023550203A (ja) | 2023-11-30 |
| ES3005966T3 (en) | 2025-03-17 |
| MX2023004426A (es) | 2023-08-04 |
| LT4228676T (lt) | 2025-02-10 |
| CN117098547A (zh) | 2023-11-21 |
| HUE070409T2 (hu) | 2025-06-28 |
| HRP20250193T1 (hr) | 2025-04-11 |
| SA523440271B1 (ar) | 2025-04-10 |
| EP4534073A2 (en) | 2025-04-09 |
| EP4228676A1 (en) | 2023-08-23 |
| US20230381285A1 (en) | 2023-11-30 |
| SI4228676T1 (sl) | 2025-03-31 |
| WO2022086953A1 (en) | 2022-04-28 |
| TWI912393B (zh) | 2026-01-21 |
| KR20230113287A (ko) | 2023-07-28 |
| CA3194764A1 (en) | 2022-04-28 |
| EP4534073A3 (en) | 2025-05-14 |
| RS66493B1 (sr) | 2025-03-31 |
| DK4228676T3 (da) | 2025-01-20 |
| PL4228676T3 (pl) | 2025-04-07 |
| EP4228676B1 (en) | 2025-01-08 |
| JP7827315B2 (ja) | 2026-03-10 |
| ZA202303162B (en) | 2024-08-28 |
| TW202233228A (zh) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7202272B2 (ja) | インスリン分泌性ペプチドの安定な水性非経口医薬組成物 | |
| ES2393180T3 (es) | Preparados de insulina libre de cinc o con bajo contenido en cinc con estabilidad mejorada | |
| US6174856B1 (en) | Stabilized insulin compositions | |
| HRP20250193T1 (hr) | Tvari prikladne za uporabu na novorođenčadima | |
| US6906028B2 (en) | Stable insulin formulations | |
| JP2023550203A5 (cg-RX-API-DMAC10.html) | ||
| EP0618807B1 (en) | A stabilized pharmaceutical formulation comprising growth hormone and histidine | |
| KR20000076419A (ko) | 폐 투여용 무아연 인슐린 결정 조성물 | |
| JP5253501B2 (ja) | 安定化トロンビン組成物 | |
| US6150331A (en) | Human growth hormone-containing aqueous pharmaceutical composition | |
| US20080249017A1 (en) | Pharmaceutical formulations of ghrh molecules | |
| US5028587A (en) | Mixed crystals of insulin and insulin derivatives | |
| JP2002512973A (ja) | タンパク質製剤 | |
| US20090163421A1 (en) | Room Temperature Stable, Lyophilized Natriuretic Peptide Formulations | |
| EP1283051B1 (en) | Stable insulin formulations | |
| JP2001518915A (ja) | インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法 | |
| US20260055163A1 (en) | Formulations comprising actriia protein variants | |
| EP4719452A1 (en) | Compositions comprising trem-1 inhibitors and uses thereof | |
| JP2025502349A5 (cg-RX-API-DMAC10.html) | ||
| JP2025502349A (ja) | Ｉｇｆ－１／ｉｇｆｂｐの酸化を低減するための組成物および方法 | |
| JPH05170664A (ja) | 安定なペプチド医薬組成物 | |
| JPH0892125A (ja) | 水性医薬組成物 | |
| CN121851107A (zh) | 一种载脂蛋白e模拟肽的芳酸盐及其制备方法和医药应用 | |
| JPH10298102A (ja) | カルシトニン注射液 | |
| JPH01233230A (ja) | 経粘膜吸収促進剤及びこれを用いた点鼻剤 |